Shortened DR TB Treatment Offers Ray Of Hope For TB Patients

A Study by the International Union Against Tuberculosis and Lung Disease (The Union) shows long-term effectiveness for shortened DR-TB treatment regimen up to 24 months after treatment completion Results from a Union-led observational study (1) published in The Lancet’s EClinicalMedicine, show that a nine-month shortened treatment regimen for rifampicin-resistant tuberculosis (RR-TB) delivered to patients under programmatic conditions maintains a good level of effectiveness up to 24 months after completion. Until now there has been limited data on the long-term effectiveness of this treatment regimen after completion. The study reports on…

Share
Read More

Zim Annual TB Incidence Falls By 8%

CASES of new Tuberculosis (TB) infections have declined by 8% at the back of improved access to TB screening treatment and care at community level. By Michael Gwarisa The incidence of tuberculosis (TB) is defined as the number of new TB cases in one year per 100,000 population whereas  prevalence of tuberculosis is defined as the number of TB cases in a population at a given point in time (sometimes referred to as “point prevalence”) per 100,000 population Speaking at the Mid Term Review of the Zimbabwe National TB program,…

Share
Read More

Drug Resistant TB Treatment Efforts Under Threat says MSF

By Michael Gwarisa Doctors Without Borders/Médecins Sans Frontières (MSF) says limited access to to new drug delamanid reduces promising treatment options available for those with drug-resistant tuberculosis. According to MSF, almost three quarters (74%) of patients receiving a combination of these drugs for six months achieved ‘culture conversion’, an early indicator that treatment might ultimately be successful. “The WHO endorses delamanid to replace the injectable agent for children and adolescents with DR-TB in cases of intolerance or resistance to some drugs, giving this group an option that is more effective and…

Share
Read More